SLC5A2 and atherosclerosis: There is abundant evidence from animal studies showing that SGLT2 inhibitors slow down the progression of atherosclerosis and exert an anti-inflammatory effect by reducing the expression of proinflammatory cytokines, including TNF-α, IL-1β, IL-6, MCP-1, ICAM, VCAM [69].